SCHEMBL9106751

SCHEMBL9106751

O=C(Cn1cccn1)Nc1cc(-c2nc(-c3nnc[nH]3)c(-c3ccccc3Cl)o2)ccn1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 7/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
NTRK1 P04629 1/20 0.35
NR3C2 P08235 1/20 0.35
MAPK14 Q16539 10/20 0.34
NR4A2 P43354 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
MAPK13 O15264 1/20 0.32
MAPK12 P53778 1/20 0.32
MAPK11 Q15759 1/20 0.32
AURKA O14965 1/20 0.32
GSK3A P49840 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
GLS O94925 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626224 0.88 JAK2 (0.42) GSK3BKDM4ENPC1MAPTRAB9A
SCHEMBL9104647 0.86 CDC7 (0.42) GSK3BKDM4ENPC1MAPTRAB9A
SCHEMBL9108071 0.86 MAPK14 (0.46) GSK3BRAB9AMAPK14NR4A2SMN1; SMN2
SCHEMBL9105551 0.84 MAPK14 (0.41) GSK3BRAB9AMAPK14GSK3A
SCHEMBL9104044 0.84 MEN1 (0.40) GSK3BKDM4ENPC1MAPTRAB9A
SCHEMBL9110056 0.84 MAPK14 (0.41) GSK3BKDM4ENPC1MAPTRAB9A
SCHEMBL9109816 0.83 MAPK8 (0.48) GSK3BKDM4ENPC1MAPTRAB9A
SCHEMBL9108971 0.83 GSK3B (0.36) GSK3BKDM4ENPC1MAPTRAB9A
SCHEMBL9890572 0.82 GSK3B (0.49) GSK3BMAPK14GSK3A
SCHEMBL10183635 0.76 NR3C2 (0.34) GSK3BKDM4ENPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142732-A1 HETEROARYLS AND USES THEREOF PIK3R4, PIK3C2B, PIK3R1 GSK3B 734/4885KDM4E 2506/4885NPC1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.